Patent Portfolio Management Toolkit: Harvesting, Budgeting, Maintenance, and Pruning

By Casey Scott McKay · 2024-11-10

A patent portfolio is a recurring expense that either supports the business or does not, and most portfolios contain a substantial fraction that does neither. This toolkit runs portfolio management from invention harvesting through the annual pruning decision, and routes each stage to the Marksy documents that do the work. It covers a disclosure process engineers will actually use, the triage that decides file, publish, or keep secret, the inventory and product mapping that reveal what the portfolio actually covers, the twenty-year budget model that should govern filing decisions, the maintenance windows that are the only structured opportunity to abandon, and the continuation strategy that keeps a family able to respond. It closes with valuation, monetization, diligence readiness, and board reporting, plus the reading path, the authorities table, and the forms.

IP and Technology > Patent Counseling Transactions | Toolkit | Published 10 November 2024 - Updated 18 December 2024 | Casey Scott McKay - marksy.us

Summary. A patent portfolio is a recurring expense that either supports the business or does not, and most portfolios contain a substantial fraction that does neither. This toolkit runs portfolio management from invention harvesting through the annual pruning decision, and routes each stage to the Marksy documents that do the work. It covers a disclosure process engineers will actually use, the triage that decides file, publish, or keep secret, the inventory and product mapping that reveal what the portfolio actually covers, the twenty-year budget model that should govern filing decisions, the maintenance windows that are the only structured opportunity to abandon, and the continuation strategy that keeps a family able to respond. It closes with valuation, monetization, diligence readiness, and board reporting, plus the reading path, the authorities table, and the forms.

Keywords: invention harvesting · disclosure process · triage · filing decision · defensive publication · portfolio inventory · family mapping · claim scope audit · product mapping · budget model · maintenance fees · annuity decisions · pruning · abandonment · continuation strategy · competitor monitoring · portfolio valuation · licensing and sale · diligence readiness · board reporting

Start Here

Ostrander Controls has ninety-one patents and applications across eleven jurisdictions, an annual intellectual property budget that grew forty percent in three years, and a new general counsel who has been asked one question by the board: what is this for?

Nobody can answer it, and four facts explain why.

Nobody has mapped the portfolio to the product line. Twenty-two families were filed on technology the company no longer sells.

The filing decision has been "file it" for eight years. Every invention disclosure that reached counsel became an application, because declining felt like a judgment on an engineer.

Maintenance fees are paid automatically. No one has ever declined to pay one, and the three-fee schedule under the domestic statute plus annuities in ten other jurisdictions is now the largest line in the budget.

And not one family has a pending continuation. Every application was prosecuted to issuance and closed, which means the portfolio cannot respond to anything a competitor does next year.

This toolkit answers three questions.

What do we have, and what does it cover? An inventory mapped to products and to competitors, which most companies have never built.
What should we file, and what should we not? Triage with real criteria, including the options that are not filing.
What should we stop paying for? Pruning at the maintenance windows, which are the only structured opportunity to reduce a portfolio's cost.

If you read only one thing, read The Priority Chain. Portfolio management is date management, and the dates it describes are the ones that govern.

Stage One: Harvesting

The problem. Inventions are made by people who do not think of themselves as inventors, in the ordinary course of solving problems, and they are never reported.

The disclosure form. One page. What problem was solved, how, what alternatives were considered, whether it has been disclosed, and who contributed. Anything longer will not be filled in.

The response time. Two weeks to an answer. A process that takes three months teaches engineers that disclosure is pointless.

The prompts. Design reviews, project completions, and release milestones are where inventions surface. A standing agenda item at each is worth more than an annual reminder.

Recognition. A modest award at disclosure, another at filing, and public acknowledgment. This is a program design question rather than a legal one and it determines the disclosure rate.

The inventor conversation. A short discussion with an attorney frequently surfaces two or three additional inventions the engineer did not think were patentable. This is the highest-yield hour in the entire program.

Contributions from outside engineering. Manufacturing process improvements, service techniques, and software tooling are inventions and they are never disclosed because nobody asks those teams.

What to capture regardless of filing. The dated record of conception, which decides inventorship disputes and supports antedating where it remains available. 37 C.F.R. § 1.131.

Stage Two: Triage

Every disclosure gets one of four answers, and only one of them is filing.

File. Where the invention is likely patentable, detectable in a competitor's product, and relevant to a product line the company intends to defend.

Keep as a trade secret. Where the invention is not detectable from the product, where the commercial life exceeds twenty years, or where disclosure would teach competitors more than exclusion would prevent. Manufacturing processes are the classic case. 18 U.S.C. § 1839. See Choosing Your Protection Toolkit.

Publish defensively. Where the company does not want a patent but wants to prevent anyone else from obtaining one. A dated publication becomes prior art, it costs almost nothing, and it forecloses the competitor's filing.

Do nothing. Where the invention is incremental, undetectable, and commercially marginal. This is a legitimate answer and it should be recorded as a decision.

The criteria to apply. Detectability — can infringement be seen from the outside. Design-around difficulty — is there another way to achieve the result. Product relevance — does it cover something the company sells or will sell. Competitive relevance — would a competitor need it. Term relevance — will the technology still matter in fifteen years. And the eligibility screen, because a claim to a result implemented on generic components will consume prosecution budget and produce a vulnerable patent. 35 U.S.C. § 101.

The failure mode. Filing everything, which is what Ostrander did for eight years. It is the most expensive possible policy and it feels like the most supportive one.

Stage Three: The Inventory

Most companies have a docket. Few have an inventory, and the difference is the mapping.

Per family, record. The family members and jurisdictions. Status and next deadline. The independent claim scope in one sentence. The product or products it covers. The competitor products it plausibly reads on. Whether a continuation is pending. The expiry date. The annual cost. And the reason it was filed.

The one-sentence claim scope is the hardest and most valuable field. A portfolio where nobody can state what claim 1 covers is a portfolio nobody can use.

Map to products. Which families cover which product lines, and which product lines are covered by nothing. Gaps and orphans both appear immediately, and both are actionable.

Map to competitors. Which families plausibly read on a competitor's shipping product. This is the field that converts a cost center into an asset, and it requires charting rather than guessing.

Flag the orphans. Families covering discontinued products, abandoned research directions, and technology the company no longer uses. Ostrander has twenty-two.

Flag the crown jewels. The small number of families that cover core products and read on competitors. These get continuations, foreign coverage, and attention.

Record the encumbrances. Licenses granted, obligations to license, security interests, and government funding under 35 U.S.C. § 202.

Keep it current, because an inventory built once and abandoned is a snapshot of a portfolio that no longer exists.

Stage Four: The Budget Model

Model twenty years, not one. A filing decision commits the company to prosecution, issuance, and maintenance across the term in every jurisdiction. The filing fee is the smallest number in the sequence.

The cost curve per family. Drafting and filing. Prosecution across two to four office actions. Foreign entry with translations. Issuance. Then maintenance at defined intervals under 35 U.S.C. § 41 domestically, and annuities annually in most other jurisdictions, escalating.

The compounding effect. Ten new families a year, each maintained for twenty years, produces a steady-state cost roughly ten times the annual filing cost. This is why portfolios grow expensive without anyone deciding they should.

The three levers. How many families are filed. How many jurisdictions each enters. How long each is maintained. The third is the one nobody uses.

Model before filing, not after. A family that will be filed in eight jurisdictions has a twenty-year cost that should be visible when the filing decision is made.

Report the curve to finance annually, with the committed cost of the existing portfolio separated from the discretionary cost of new filings. Finance departments consistently believe patent cost is discretionary and it is largely not.

Stage Five: Maintenance and Pruning

The windows. Domestic maintenance fees fall due at defined intervals under 35 U.S.C. § 41, with a grace period and a surcharge, and lapse ends the patent. Foreign annuities fall annually. These are the only structured opportunities to reduce a portfolio's cost, and most companies pay them without a decision.

Make each one a decision. The default should be abandon unless someone affirmatively decides to keep. Reversing the default is the single highest-impact change available in portfolio management.

The questions per family. Does it cover a product the company still sells? Does it read on a competitor's product? Has it been licensed or is it likely to be? Does it block a competitor from a direction the company cares about? Would abandoning it embarrass the company in a negotiation? And what does the next fee cost across all jurisdictions?

Where the answer is no to all of them, abandon. A patent that covers nothing the company sells, reads on nothing a competitor sells, and blocks nothing is a certificate the company is renting.

Prune by jurisdiction, not only by family. A family worth keeping domestically may not be worth annuities in seven other countries.

Consider selling rather than abandoning. A patent with no value to the company may have value to someone whose product it reads on, and brokered sales of pruned families are a real market.

Consider donating or dedicating where a tax or reputational benefit exists and the patent is genuinely surplus.

Document every abandonment decision. A buyer asking why a family was dropped should receive an answer, and "nobody paid the fee" is not one.

Stage Six: Continuations

Keep at least one pending in every family that matters. A continuation permits claims drafted against a competitor's product with a priority date from the original filing. This is the single most valuable prosecution habit.

The cost. A filing fee at each issuance, plus prosecution of whatever is claimed, plus eventual maintenance. Real but small against the option it preserves.

The rule. For any family covering a defended product line, file a continuation at every issuance unless someone affirmatively decides otherwise.

When to use it. A competitor ships something the existing claims do not quite reach. Draft claims to their product, supported by the original specification, and prosecute them. This is lawful, ordinary, and it is why continuation practice exists.

The limit. New matter cannot be added. A continuation claims only what the original specification describes and enables, which is why the specification's breadth on the filing date determines everything a family can ever become. 35 U.S.C. § 112; 35 U.S.C. § 120.

Divisionals preserve claims subject to a restriction requirement and carry safe-harbor protection under 35 U.S.C. § 121, and they must be filed before the parent issues.

The trap Ostrander fell into. Prosecuting every family to issuance and closing it. The portfolio is now a set of fixed claim sets that cannot adapt, and rebuilding that flexibility requires new filings with today's priority dates.

Stage Seven: Monitoring

Watch competitors' filings. Published applications signal direction eighteen months in advance, and they are free to read.

Watch competitors' products. Marked products, technical documentation, and teardowns feed both the infringement analysis and the freedom-to-operate refresh.

Watch assignment records for portfolios moving to assertion entities.

Watch the art that surfaces. Anything found in a search, a foreign office action, a competitor's citation, or a customer's request for proposal is potentially material to pending applications under 37 C.F.R. § 1.56, and the flow into the file fails routinely.

Watch for oppositions and challenges against the company's own foreign patents, which run on short windows.

Feed it all into the annual review, because monitoring that produces no decisions is a subscription rather than a program.

Stage Eight: Valuation and Monetization

Portfolios are valued three ways, and clients conflate them. Cost — what was spent, which says nothing about worth. Market — what comparable portfolios sold for, which requires comparables that rarely exist. Income — what it generates or could generate through licensing or exclusion, which is the only measure that reflects value and the hardest to establish.

What makes a family valuable. Claims that read on a product someone else sells. A clean chain of title. A prosecution record that survives scrutiny. Remaining term. Foreign coverage in jurisdictions where enforcement works. And a pending continuation.

What makes a family worthless. Claims that read only on the company's own implementation. A defective chain of title. Narrow claims obtained by heavy amendment. Short remaining term. And no detectability.

Licensing out. Requires identifying who practices the claims, charting it, and approaching — which reveals the company's interest and starts a negotiation it must be prepared to finish. See Patent Licensing and Technology Transfer Toolkit.

Selling. A brokered sale of families the company will not assert, which converts a maintenance liability into cash and creates a patent in someone else's hands that may be asserted against the company's customers.

Collateral. Patents secure lending, and the security interest recordation and the chain of title both need to be clean.

Stage Nine: Diligence Readiness

What a buyer asks for. The inventory. The chain of title for every family, with executed assignments. Encumbrances — licenses, obligations, security interests, and government funding. The prosecution files. Maintenance status. Pending deadlines. Any challenges or assertions. And the product mapping.

What sinks a deal. A missing inventor assignment. An undisclosed license. Government funding nobody flagged under 35 U.S.C. § 202. A lapsed patent nobody noticed. And an inventory that does not match the docket.

The assignment problem specifically. An inventor who never executed a present-tense assignment leaves a patent the company does not own. 35 U.S.C. § 261. This is the most common diligence finding in patent portfolios and it is entirely preventable at hire.

Fix it before the transaction. Confirmatory assignments, recordal, and a clean inventory are cheap in the ordinary course and expensive under a deadline.

Stage Ten: Board Reporting

One page, annually, with four things.

What the portfolio covers. Products protected, products unprotected, and where competitors are covered.

What it costs. Committed cost of the existing portfolio, discretionary cost of new filings, and the twenty-year curve.

What changed. Filed, issued, abandoned, licensed, and challenged.

What is at risk. Products with no coverage, families expiring, jurisdictions being exited, and any assertion or challenge pending.

Why this matters. A board that receives this annually understands the budget. A board that receives nothing asks Ostrander's question at the worst possible moment, which is after the number has grown forty percent.

Ostrander's Four Facts, Addressed

The unmapped portfolio. Building the mapping is eight to twelve weeks of work for ninety-one families, and it is the only way to answer the board's question. The output is three lists: families covering current products, families covering nothing the company sells, and families plausibly reading on competitors. The third list is short and it is the entire commercial case for the portfolio. The second list is twenty-two families and it is the pruning candidate set.

The file-everything policy. Declining to file feels like a judgment on an engineer, which is why the policy persists. The fix is to change what declining means: a disclosure that is not filed can be published defensively, kept as a documented trade secret, or recorded as a decision — and each of those is an outcome rather than a rejection. Pair it with recognition at disclosure rather than only at filing, so the incentive survives the change.

Automatic maintenance payments. Reverse the default. Every fee becomes a decision, with abandon as the presumption and an affirmative reason required to keep. For a portfolio of ninety-one families across eleven jurisdictions, this is the single largest available cost reduction and it requires no new spending to implement.

No pending continuations. The flexibility cannot be recovered for issued families; it can be built going forward. Adopt a standing rule that every family covering a defended product line gets a continuation at issuance unless someone decides otherwise. For the crown-jewel families already issued, consider whether any sibling application is still pending and whether a new filing on current technology is warranted.

What the board should be told. That the portfolio was built without a strategy, that mapping it will take a quarter, that the answer will likely be that a third of it can be abandoned, and that the savings will be redirected into continuations and foreign coverage for the families that matter. That is a credible answer and it is better received than a defense of the status quo.

The Annual Review, Run Properly

Timing. One meeting a year, scheduled against the maintenance fee calendar so that decisions can actually be implemented.

Attendees. Counsel, the head of engineering, a product leader, and finance. A review conducted by legal alone produces legal answers to commercial questions.

Inputs. The inventory. The product roadmap. The competitor monitoring output. The budget curve. And a list of every fee falling due in the next twelve months.

The agenda, in order. What did we file and why. What issued and what does it cover. What is coming due. What should be abandoned. What needs continuations. Where are the coverage gaps. What did competitors file. And what should next year's filing budget be.

The output. A decision per family with a fee due. A filing plan for the coming year. A list of coverage gaps with owners. And the one-page board report.

The discipline that makes it work. Every family with a fee due appears on the agenda, and the meeting does not end until each has a decision. A review that discusses the interesting families and pays the rest by default is a review that changed nothing.

Half-day, once a year. That is the entire governance burden, and it is what separates a portfolio from a subscription.

What a Portfolio Is Actually For

Clients ask what the portfolio is for and receive an abstraction. There are five concrete answers and a portfolio should be built for whichever apply.

Exclusion. Stopping a competitor from selling something. The classic purpose and the rarest in practice, because it requires claims that read on a competitor's product, a willingness to litigate, and a forum that grants injunctions. Most portfolios cannot do this and were not built to.

Deterrence. Making a competitor's counsel advise against a design direction. This requires only that the patents be visible and plausibly relevant, which is a much lower bar, and it is where a large share of portfolio value actually sits.

Freedom to operate through cross-licensing. A company with patents a competitor needs can trade rather than pay. This is the dominant use of patents in industries where everyone infringes everyone, and it values breadth of coverage over depth.

Revenue. Licensing or selling. Requires detectability, claims reading on someone else's product, and a willingness to run the negotiation to its conclusion.

Valuation and financing. Investors, acquirers, and lenders price patents, sometimes crudely. A portfolio that supports a valuation story has value even if it is never asserted, and this is the purpose most portfolios actually serve.

Why naming the purpose matters. A portfolio built for deterrence should be broad and visible. One built for exclusion should be narrow, deep, and prosecuted with a litigator's eye. One built for cross-licensing should cover many directions shallowly. One built for revenue should cover what others sell. These are different portfolios and a company that has not chosen ends up with none of them.

The Coverage Gap Analysis

The most useful output of the product mapping is the list of what is not covered.

Products with no patent coverage. Common, and frequently the company's most profitable line, because the invention happened before anyone was thinking about filing.

Features competitors would want. The distinctive capability the sales team leads with, unpatented, and free for anyone to copy.

Directions the company is heading. Coverage should anticipate the roadmap, and filings on next year's product are cheaper and broader than filings on last year's.

Directions competitors are heading, visible in their published applications eighteen months in advance under 35 U.S.C. § 122. Filing into a direction a competitor is pursuing is where blocking positions come from.

Improvements the company made and never disclosed. The harvesting process should be run retrospectively once, across the last three years of engineering work, because the yield is usually substantial and nobody has ever asked.

Where the gap cannot be closed. Public disclosure, sale, or use more than a year ago forecloses filing domestically and immediately forecloses it abroad. 35 U.S.C. § 102. The honest answer for those is a trade secret program where the information remains protectable, and nothing where it does not.

The output. A prioritized filing plan for the coming year, driven by gaps and by roadmap rather than by whichever engineer submitted a disclosure.

Who Runs It

Portfolio management fails on ownership more often than on analysis, and the roles are worth naming.

One accountable owner. Usually intellectual property counsel or, in smaller companies, the general counsel. Not a committee, and not outside counsel, because outside counsel is paid per matter and the pruning decision reduces their fees.

An engineering champion. A respected technical person who prompts disclosures, sits in the triage, and translates between the two vocabularies. This role determines the disclosure rate more than any process document.

A product voice in the annual review, because the questions about what the company still sells and where it is heading are product questions.

Finance, once a year, to see the twenty-year curve and to understand that most of the cost is committed rather than discretionary.

Outside counsel with a clear brief. Prosecute toward a commercial objective, flag when narrowing has gone past usefulness, and recommend abandonment where it is warranted. A firm that never recommends abandoning anything is not managing a portfolio.

A docket administrator with the deadlines in two systems, because the failure mode is administrative.

And a written charter, short, saying what the portfolio is for and who decides. Ostrander's problem is not that it lacked people; it is that nobody had been asked to decide anything.

The Trade Secret Alternative

Every triage decision to file is also a decision not to keep something secret, and the trade runs one way.

Filing publishes. An application publishes at eighteen months under 35 U.S.C. § 122, which ends secrecy in what it discloses and teaches competitors exactly what the company is doing. A non-publication request is available only where no foreign filing will occur.

Secrecy has no term. A trade secret protected under 18 U.S.C. § 1839 lasts as long as it stays secret, which for a manufacturing process can exceed a patent term substantially.

Secrecy has no exclusion. Independent development and reverse engineering are both proper, and a competitor who works it out owes nothing.

Detectability decides it. Where infringement would be visible from the product, patent. Where it would not — a process, a formulation, an internal method — the patent teaches the competitor and the claim cannot be enforced because nobody can prove infringement.

Reasonable measures are required for trade secret protection, which means a decision to keep something secret has an ongoing compliance cost that a filing decision does not.

The hybrid. Patent the detectable aspects, keep the process secret, and be deliberate about what the specification discloses — because a specification describing the secret process to satisfy the enablement requirement under 35 U.S.C. § 112 has published it.

Record the decision either way, because the trade secret claim later depends on showing the information was treated as secret from the start.

Six Numbers Worth Tracking

A portfolio program is measurable, and six numbers describe it better than any narrative.

Disclosure rate. Disclosures received per engineer per year. A low number means the harvesting process is not working, not that the engineers are uninventive.

Conversion rate. Disclosures that become filings. A rate near one hundred percent means there is no triage. A very low rate means the disclosure process is capturing noise.

Coverage ratio. Product lines with at least one family reading on them, over total product lines. This is the number the board actually wants and almost nobody computes it.

Competitor read rate. Families plausibly reading on a competitor's shipping product, over total families. Usually small, and it is where the portfolio's commercial value concentrates.

Cost per maintained family per year, across all jurisdictions. It rises silently as foreign annuities escalate, and it is the number that explains a budget growing forty percent in three years.

Abandonment rate. Families abandoned per year, over families with fees due. A rate of zero means nobody is deciding, which was Ostrander's situation and is the most common one.

What to do with them. Put all six on the annual board page with a three-year trend. They convert an argument about whether the portfolio is worth its cost into a discussion about which of six numbers should change.

Starting From Nothing

A company with no program and a growing engineering team should do four things in the first year, in order.

Fix the assignments. Present-tense assignment language in every employment and contractor agreement, executed at hire, with confirmatory assignments for anyone already on staff who never signed one. 35 U.S.C. § 261. This costs a template and an afternoon and it prevents the most common diligence finding.

Put in the disclosure control. Anything going outside the company that describes an unfiled invention goes past counsel first. One rule, four functions briefed, and it preserves more value than any filing strategy.

Run the harvest retrospectively once. Three years of engineering work, reviewed with the team, looking for what was never disclosed. The yield is usually substantial, and the grace period under 35 U.S.C. § 102(b) means some of it is still filable domestically even if foreign rights are gone.

Build the inventory as you go, rather than as a project later. Every filing gets its row, with the claim scope in a sentence and the product mapping, on the day it is filed.

Then set the annual review and let the program run. Everything else in this toolkit is refinement.

A Suggested Reading Path

If you are building the program:

If you are deciding what to file:

If you are deciding what to keep:

Primary Authorities

| Authority | Proposition | |---|---| | 35 U.S.C. § 41 | Maintenance fees; the pruning windows | | 35 U.S.C. § 101 | Eligibility screen at triage | | 35 U.S.C. § 102 | Novelty; defensive publication as prior art | | 35 U.S.C. § 103 | Obviousness | | 35 U.S.C. § 112 | Disclosure; the ceiling on continuations | | 35 U.S.C. § 120 | Benefit; continuation priority | | 35 U.S.C. § 121 | Divisionals; safe harbor | | 35 U.S.C. § 122 | Publication; competitor monitoring | | 35 U.S.C. § 154 | Term; expiry planning | | 35 U.S.C. § 202 | Federally funded inventions; encumbrance | | 35 U.S.C. § 261 | Assignment; chain of title | | 35 U.S.C. § 262 | Joint owners | | 35 U.S.C. § 271 | Infringing acts; competitor mapping | | 35 U.S.C. § 287 | Marking; the damages period | | 35 U.S.C. § 311 | Inter partes review; challenge exposure | | 18 U.S.C. § 1839 | Trade secret; the alternative to filing | | 37 C.F.R. § 1.56 | Duty of disclosure across a family | | 37 C.F.R. § 1.131 | Antedating; the value of dated records | | 37 C.F.R. § 1.321 | Terminal disclaimers; common ownership |

Forms and Templates

The Portfolio Inventory Template is the central artifact of this toolkit — family, jurisdiction, status, claim scope in a sentence, product mapping, competitor mapping, continuation status, expiry, annual cost, and the reason it was filed. A company that maintains it can answer the board's question in a meeting; one that does not spends six weeks reconstructing it during diligence. The Assignment Agreement Template supplies the present-tense language that prevents the most common diligence finding, and it belongs in the hiring packet rather than in the filing packet. The License Agreement Template is the instrument for monetizing what the inventory identifies as valuable. The Office Action Response Template keeps prosecution consistent across a portfolio large enough that several people are writing responses.

Related Toolkits and Checklists

For the doctrine underlying the filing decision, the Patent Fundamentals Toolkit covers eligibility, novelty, obviousness, and disclosure. For the mechanics of getting applications allowed, the Patent Prosecution Toolkit supplies the sequence and the docketing discipline. For the jurisdiction decisions that drive most of the cost, the International Patent Toolkit supplies the country model. For monetizing what the inventory identifies, the Patent Licensing and Technology Transfer Toolkit covers the negotiation. And for the threshold question at triage, the Choosing Your Protection Toolkit runs patent against copyright, trademark, and trade secrecy.